CD95 CHO Cell Line (Medium or High Expression)

Only %1 left
Catalog #
78499
As low as $7,150 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The CD95 CHO cell line is a recombinant clonal stable CHO cell line constitutively expressing full-length human CD95 receptor (accession number: NM_000043.3). Surface expression of human CD95 was confirmed by flow cytometry. Each clonal cell line was selected for different levels of CD95 expression (High or Medium) to mimic varying CD95 expression levels in cancer cells.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
FAS, APT1, FAS1, TNFRSF6, Tumor necrosis factor receptor superfamily member 6
Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent
Species
Human
Supplied As
Each vial contains 2 x 106 cells in 1 ml of cell freezing medium (BPS Bioscience #79796)
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3B BPS Bioscience #79529

Materials Required for Cellular Assay

Name Ordering Information
F-12K Medium (Kaighn’s Modification of Ham’s F-12 Medium) ThermoFisher #21127030
ELANE (Elastase), Avi-His-Tag HiP™ Recombinant BPS Bioscience #101141
Recombinant Mouse Active Cathepsin C/DPPI Protein, CF R&D Systems #2336-CY-010
96-well Flat Clear Bottom White Polystyrene TC-treated Microplates Corning #3610
Caspase-Glo® 3/7 Assay System Promega #G8091
Genbank #
NM_000043.3
UniProt #
P25445
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

CD95 (Fas, APO-1, TNFRSF6) is a transmembrane cell-surface receptor with multifunctional regulatory effects in apoptosis and proliferation regulation. In some cellular contexts, interactions with the receptor ligand (CD95L) have been shown to activate JNK, ERK1, and NF-kB pathways to induce cell proliferation. In other cases, ligand interactions can trigger the release of a cytoplasmic death domain and induce apoptosis. This function is used by the immune system to kill cancer cells, and consequently, cancer cells can become resistant to CD95-induced apoptosis. The overexpression of CD95 in this cell line allows for the rapid testing of novel therapeutics that aim to increase CD95-mediated apoptosis in cancer cells.